355 related articles for article (PubMed ID: 26678258)
21. Analysis of intentional drug poisonings using Ohio Poison Control Center Data, 2002-2014.
Pringle K; Caupp S; Shi J; Wheeler KK; Spiller HA; Casavant MJ; Xiang H
Clin Toxicol (Phila); 2017 Aug; 55(7):652-658. PubMed ID: 28393553
[TBL] [Abstract][Full Text] [Related]
22. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
Smith KE; Staton M
Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
[No Abstract] [Full Text] [Related]
23. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
[TBL] [Abstract][Full Text] [Related]
24. Synthetic cathinone exposures reported to Texas poison centers.
Forrester MB
Am J Drug Alcohol Abuse; 2012 Nov; 38(6):609-15. PubMed ID: 22541001
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.
Spiller HA; Ryan ML; Weston RG; Jansen J
Clin Toxicol (Phila); 2011 Jul; 49(6):499-505. PubMed ID: 21824061
[TBL] [Abstract][Full Text] [Related]
26. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market.
Norman C; Walker G; McKirdy B; McDonald C; Fletcher D; Antonides LH; Sutcliffe OB; Nic Daéid N; McKenzie C
Drug Test Anal; 2020 Apr; 12(4):538-554. PubMed ID: 31944624
[TBL] [Abstract][Full Text] [Related]
27. Synthetic cannabinoid and marijuana exposures reported to poison centers.
Forrester MB; Kleinschmidt K; Schwarz E; Young A
Hum Exp Toxicol; 2012 Oct; 31(10):1006-11. PubMed ID: 22859662
[TBL] [Abstract][Full Text] [Related]
28. Psychoactive substances--some new, some old: a scan of the situation in the U.S.
Maxwell JC
Drug Alcohol Depend; 2014 Jan; 134():71-77. PubMed ID: 24140401
[TBL] [Abstract][Full Text] [Related]
29. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.
Helander A; Bäckberg M; Beck O
PLoS One; 2020; 15(4):e0232038. PubMed ID: 32324788
[TBL] [Abstract][Full Text] [Related]
30. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN).
Dines AM; Wood DM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Sedefov R; Dargan PI;
Clin Toxicol (Phila); 2015 Nov; 53(9):893-900. PubMed ID: 26503789
[TBL] [Abstract][Full Text] [Related]
31. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre.
Hondebrink L; Nugteren-van Lonkhuyzen JJ; Van Der Gouwe D; Brunt TM
Drug Alcohol Depend; 2015 Feb; 147():109-15. PubMed ID: 25541244
[TBL] [Abstract][Full Text] [Related]
32. Adolescent synthetic cannabinoid exposures reported to Texas poison centers.
Forrester MB
Pediatr Emerg Care; 2012 Oct; 28(10):985-9. PubMed ID: 23023462
[TBL] [Abstract][Full Text] [Related]
33. Methamphetamine exposures reported to United States poison control centers, 2000-2019.
Chen T; Spiller HA; Badeti J; Funk AR; Zhu M; Smith GA
Clin Toxicol (Phila); 2021 Aug; 59(8):705-714. PubMed ID: 33403876
[TBL] [Abstract][Full Text] [Related]
34. New psychoactive substance use as a survival strategy in rural marginalised communities in Hungary.
Csák R; Szécsi J; Kassai S; Márványkövi F; Rácz J
Int J Drug Policy; 2020 Nov; 85():102639. PubMed ID: 31911024
[TBL] [Abstract][Full Text] [Related]
35. Status and trends in poisonings in Denmark 2007-2009.
Bøgevig S; Høgberg LC; Dalhoff KP; Mortensen OS
Dan Med Bull; 2011 May; 58(5):A4268. PubMed ID: 21535985
[TBL] [Abstract][Full Text] [Related]
36. "Bath salts" and "plant food" products: the experience of one regional US poison center.
Murphy CM; Dulaney AR; Beuhler MC; Kacinko S
J Med Toxicol; 2013 Mar; 9(1):42-8. PubMed ID: 22733603
[TBL] [Abstract][Full Text] [Related]
37. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
Sande M
Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
[TBL] [Abstract][Full Text] [Related]
39. Adolescent exposures to traditional and novel psychoactive drugs, reported to National Poison Data System (NPDS), 2007-2017.
Ng PC; Banerji S; Graham J; Leonard J; Wang GS
Drug Alcohol Depend; 2019 Sep; 202():1-5. PubMed ID: 31279256
[TBL] [Abstract][Full Text] [Related]
40. Recreational phenethylamine poisonings reported to a French poison control center.
Le Roux G; Bruneau C; Lelièvre B; Bretaudeau Deguigne M; Turcant A; Harry P; Boels D
Drug Alcohol Depend; 2015 Sep; 154():46-53. PubMed ID: 26205314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
